1986
DOI: 10.1016/s0140-6736(86)92714-5
|View full text |Cite
|
Sign up to set email alerts
|

Valproate Toxicity and Ornithine Carbamoyltransferase Deficiency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
18
0
1

Year Published

1991
1991
2014
2014

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 57 publications
(19 citation statements)
references
References 0 publications
0
18
0
1
Order By: Relevance
“…This encephalopathy is most common after initiation of treatment with VPA, but also after associating a second antiepileptic agent [7][8][9]. A few cases of VPAinduced hyperammonemic encephalopathy have been described in patients with inborn errors of the hepatic ammonia metabolism (urea cycle defects) [10,11].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This encephalopathy is most common after initiation of treatment with VPA, but also after associating a second antiepileptic agent [7][8][9]. A few cases of VPAinduced hyperammonemic encephalopathy have been described in patients with inborn errors of the hepatic ammonia metabolism (urea cycle defects) [10,11].…”
Section: Discussionmentioning
confidence: 99%
“…First, the renal production of ammonia is increased by means of an enhanced glutaminase activity. Second, there is a reduction of the hepatic fatty acid metabolism by a reduced availability of carnitine and an inhibition of carbamoylphosphate synthetase [9,11,12]. Both mechanisms cause hyperammonemia.…”
Section: Discussionmentioning
confidence: 99%
“…The decreased blood glutamine level observed in our study might support the hypothesis that ordinary short-term treatment with CFTM-PI induces ATP and acetyl-CoA insufficiency because of carnitine deficiency, CoA sequestration or a combination of both. Kay et al(1986) and Hjelm et al (1986) have reported cases in which occult metabolic disorders were revealed during the administration of VPA. In other studies, L-carnitine supplementation was tried for normalization of carnitine deficiency in VPA-treated patients (Ohtani et al 1982;Sakemi et al 1992).…”
Section: Discussionmentioning
confidence: 99%
“…It can also be used to treat bipolar depression, psychoaffective disorders, neuropathic pain and migraines (Löscher, 1999). Valproic acid-induced encephalopathy (VAE) is a rare complication and can result in death if not diagnosed early (Kay et al, 1986). VAE can be accompanied by deterioration of consciousness, focal neurological findings, ataxia, cognitive slowness, vomiting and seizures.…”
Section: Introductionmentioning
confidence: 99%